Clinical trial
Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density…
NCT00129181 · Institute for Neurodegenerative Disorders, Other · Completed
Key facts
| NCT number | NCT00129181 |
|---|---|
| Title | Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease |
| Official title | A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease |
| Lead sponsor | Institute for Neurodegenerative Disorders, Other |
| Collaborators | Pfizer Industry GE Healthcare |
| Status | Completed |
| Study type | Interventional |
| Conditions | Parkinson Disease, Parkinsonian Syndrome |
| Intervention type | Drug, Procedure |
| Interventions | cabergoline, carbidopa/levodopa, DATscan and SPECT imaging |
| Enrollment | 30 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2006 |
| Completion | Jan 1, 2007 |
| First posted | Aug 11, 2005 |
| Last update posted | Aug 28, 2009 |
| Countries | Austria, Germany, Italy, Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: